Skip to content
Research Article Open access CC BY 4.0

Malignant Melanoma of the Anorectal Region: A Case Study and Review of the Contemporary Treatment Options

Rakshita Ramesh Bhat, Namitha Prakash

Journal of Cancer and Tumor International · pp. 1–8 · Published 30 Jan 2023

10.9734/jcti/2023/v13i1225

Abstract

Aims: Anorectal melanoma, an uncommon malignancy of mucosal origin accounts for 0.05 per cent of all colorectal malignancies and 1 per cent of tumours of the anal canal. The typical clinical presentation includes local pain, palpable mass, bleeding, change in bowel habits, and weight loss. The symptoms are somewhat nondescript and unremarkable and can be easily confused with other conditions native to the region. Hence, a careful and timely assessment is imperative in treating this condition. Presentation of Case: A case involving a 54-year-old male who presented with a 3-month history of rectal bleeding and pain. Further assessment revealed a malignant melanoma of the anal canal. After undergoing laparoscopic abdominoperineal resection, the patient was on 6 cycles of dacarbazine. He was subsequently found to have liver metastasis. He subsequently started oral Temozolomide for 2 cycles. He has been on close follow-up for the last 6 months and the disease has not progressed since. Discussion: The course of evaluation in suspected cases of anorectal melanoma is a rectal examination, biopsy and histopathologic examination. Immunohistochemistry aids in the confirmation of the diagnosis. Laparoscopic abdominoperineal resection demonstrates good response rates. Adjuvant chemotherapy in anorectal melanoma can be given in patients following surgical resection of the primary anorectal tumour and with a high risk of recurrence. Targeted therapies like c-kit inhibitors, BRAF inhibitors, anti- CTLA-4 antibodies and anti-PD-1 antibodies can also be used. Conclusion: Melanomas of the anorectal region present a diagnostic dilemma and carry poor prognoses. Despite an aggressive management approach, the disease maintains an average five-year survival rate of 20%.

Mucosal melanoma bleeding per rectum dacarbazine

References (18)

  1. 1 The National Cancer Data Base report on cutaneous and noncutaneous melanoma [DOI]
  2. 2 Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma [DOI]
  3. 3 The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care [DOI]
  4. 4 The efficacy of anti‐PD‐1 agents in acral and mucosal melanoma [DOI]
  5. 5 Incidence and risk factors for the occurrence of non‐AIDS‐defining cancers among human immunodeficiency virus‐infected individuals [DOI]
  6. 6 Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma [DOI]
  7. 7 Identification of recurrent mutational events in anorectal melanoma [DOI]
  8. 8 Malignant melanoma of the anus [DOI]
  9. 9 Changing epidemiology of anorectal melanoma [DOI]
  10. 10 Surgical Therapy for Anorectal Melanoma [DOI]
  11. 11 Importance of clear resection margins in anorectal malignant melanoma [DOI]
  12. 12 Biochemotherapy in patients with metastatic anorectal mucosal melanoma [DOI]
  13. 13 Anal Versus Rectal Melanoma [DOI]
  14. 14 c-kit gene mutation and CD117 expression in human anorectal melanomas [DOI]
  15. 15 Abdominoperineal resection or local excision? a survival analysis of anorectal malignant melanoma with surgical management [DOI]
  16. 16 Treatment and outcomes of anorectal melanoma [DOI]
  17. 17 Patient characteristics, methods of diagnosis, and treatment of mucous membrane melanoma in the United States of America.
  18. 18 Endocrine cells and melanin-containing cells in the anal canal epithelium [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

28

Page views

0

PDF downloads

5

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.